FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385568795> ?p ?o ?g. }

• W4385568795 endingPage "e682" @default.
• W4385568795 startingPage "e670" @default.
• W4385568795 abstract "BackgroundFew trials have compared homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines. The aim of this study was to assess immune responses, safety, and efficacy against SARS-CoV-2 infection following homologous or heterologous third-dose COVID-19 vaccination with either one dose of CoronaVac (Sinovac Biotech; inactivated vaccine) or BNT162b2 (Fosun Pharma–BioNTech; mRNA vaccine).MethodsThis is an ongoing, randomised, allocation-concealed, open-label, comparator-controlled trial in adults aged 18 years or older enrolled from the community in Hong Kong, who had received two doses of CoronaVac or BNT162b2 at least 6 months earlier. Participants were randomly assigned, using a computer-generated sequence, in a 1:1 ratio with allocation concealment to receive a (third) dose of CoronaVac or BNT162b2 (ancestral virus strain), stratified by types of previous COVID-19 vaccination (homologous two doses of CoronaVac or BNT162b2). Participants were unmasked to group allocation after vaccination. The primary endpoint was serum neutralising antibodies against the ancestral virus at day 28 after vaccination in each group, measured as plaque reduction neutralisation test (PRNT50) geometric mean titre (GMT). Surrogate virus neutralisation test (sVNT) mean inhibition percentage and PRNT50 titres against omicron BA.1 and BA.2 subvariants were also measured. Secondary endpoints included geometric mean fold rise (GMFR) in antibody titres; incidence of solicited local and systemic adverse events; IFNγ+ CD4+ and IFNγ+ CD8+ T-cell responses at days 7 and 28; and incidence of COVID-19. Within-group comparisons of boost in immunogenicity from baseline and between-group comparisons were done according to intervention received (ie, per protocol) by paired and unpaired t test, respectively, and cumulative incidence of infection was compared using Kaplan-Meier curves and a proportional hazards model to estimate hazard ratio. The trial is registered with ClinicalTrials.gov, NCT05057169.FindingsWe enrolled participants from Nov 12, 2021, to Jan 27, 2022. We vaccinated 219 participants who previously received two doses of CoronaVac, including 101 randomly assigned to receive CoronaVac (CC-C) and 118 randomly assigned to receive BNT162b2 (CC-B) as their third dose; and 232 participants who previously received two doses of BNT162b2, including 118 randomly assigned to receive CoronaVac (BB-C) and 114 randomly assigned to receive BNT162b2 (BB-B) as their third dose. The PRNT50 GMTs on day 28 against ancestral virus were 109, 905, 92, and 816; against omicron BA.1 were 9, 75, 8, and 86; and against omicron BA.2 were 6, 80, 6, and 67 in the CC-C, CC-B, BB-C, and BB-B groups, respectively. Mean sVNT inhibition percentages on day 28 against ancestral virus were 83%, 96%, 87%, and 96%; against omicron BA.1 were 15%, 58%, 19%, and 69%; and against omicron BA.2 were 43%, 85%, 50%, and 90%, in the CC-C, CC-B, BB-C, and BB-B groups, respectively. Participants who had previously received two doses of CoronaVac and a BNT162b2 third dose had a GMFR of 12 (p<0·0001) compared with those who received a CoronaVac third dose; similarly, those who had received two doses of BNT162b2 and a BNT162b2 third dose had a GMFR of 8 (p<0·0001). No differences in CD4+ and CD8+ T-cell responses were observed between groups. We did not identify any vaccination-related hospitalisation within 1 month after vaccination. We identified 58 infections when omicron BA.2 was predominantly circulating, with cumulative incidence of 15·3% and 15·4% in the CC-C and CC-B groups, respectively (p=0·93), and 16·7% and 14·0% in the BB-C and BB-B groups, respectively (p=0·56).InterpretationSimilar levels of incidence of, presumably, omicron BA.2 infections were observed in each group despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third dose. Further research is warranted to identify appropriate correlates of protection for inactivated COVID-19 vaccines.FundingHealth and Medical Research Fund, Hong Kong.TranslationFor the Chinese translation of the abstract see Supplementary Materials section." @default.
• W4385568795 created "2023-08-05" @default.
• W4385568795 creator A5000496377 @default.
• W4385568795 creator A5006065098 @default.
• W4385568795 creator A5006489248 @default.
• W4385568795 creator A5007289151 @default.
• W4385568795 creator A5016318530 @default.
• W4385568795 creator A5021334121 @default.
• W4385568795 creator A5024880864 @default.
• W4385568795 creator A5026115438 @default.
• W4385568795 creator A5028570460 @default.
• W4385568795 creator A5032096463 @default.
• W4385568795 creator A5036046953 @default.
• W4385568795 creator A5043618382 @default.
• W4385568795 creator A5046945762 @default.
• W4385568795 creator A5047584751 @default.
• W4385568795 creator A5054554979 @default.
• W4385568795 creator A5061261084 @default.
• W4385568795 creator A5067154686 @default.
• W4385568795 creator A5070656971 @default.
• W4385568795 creator A5074151633 @default.
• W4385568795 creator A5079507122 @default.
• W4385568795 creator A5085714741 @default.
• W4385568795 creator A5062505370 @default.
• W4385568795 date "2023-09-01" @default.
• W4385568795 modified "2023-10-09" @default.
• W4385568795 title "Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial" @default.
• W4385568795 cites W2980180208 @default.
• W4385568795 cites W3097740956 @default.
• W4385568795 cites W3163785571 @default.
• W4385568795 cites W3174017401 @default.
• W4385568795 cites W3187496430 @default.
• W4385568795 cites W3192052690 @default.
• W4385568795 cites W4200274151 @default.
• W4385568795 cites W4205240144 @default.
• W4385568795 cites W4206906464 @default.
• W4385568795 cites W4206914007 @default.
• W4385568795 cites W4210450230 @default.
• W4385568795 cites W4212835565 @default.
• W4385568795 cites W4220730627 @default.
• W4385568795 cites W4225314998 @default.
• W4385568795 cites W4280594901 @default.
• W4385568795 cites W4280610129 @default.
• W4385568795 cites W4281764065 @default.
• W4385568795 cites W4281843570 @default.
• W4385568795 cites W4282922345 @default.
• W4385568795 cites W4282958946 @default.
• W4385568795 cites W4283392031 @default.
• W4385568795 cites W4285606826 @default.
• W4385568795 cites W4289653540 @default.
• W4385568795 cites W4292661323 @default.
• W4385568795 cites W4295709321 @default.
• W4385568795 cites W4308774038 @default.
• W4385568795 cites W4311823398 @default.
• W4385568795 cites W4366371403 @default.
• W4385568795 doi "https://doi.org/10.1016/s2666-5247(23)00216-1" @default.
• W4385568795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37549680" @default.
• W4385568795 hasPublicationYear "2023" @default.
• W4385568795 type Work @default.
• W4385568795 citedByCount "0" @default.
• W4385568795 crossrefType "journal-article" @default.
• W4385568795 hasAuthorship W4385568795A5000496377 @default.
• W4385568795 hasAuthorship W4385568795A5006065098 @default.
• W4385568795 hasAuthorship W4385568795A5006489248 @default.
• W4385568795 hasAuthorship W4385568795A5007289151 @default.
• W4385568795 hasAuthorship W4385568795A5016318530 @default.
• W4385568795 hasAuthorship W4385568795A5021334121 @default.
• W4385568795 hasAuthorship W4385568795A5024880864 @default.
• W4385568795 hasAuthorship W4385568795A5026115438 @default.
• W4385568795 hasAuthorship W4385568795A5028570460 @default.
• W4385568795 hasAuthorship W4385568795A5032096463 @default.
• W4385568795 hasAuthorship W4385568795A5036046953 @default.
• W4385568795 hasAuthorship W4385568795A5043618382 @default.
• W4385568795 hasAuthorship W4385568795A5046945762 @default.
• W4385568795 hasAuthorship W4385568795A5047584751 @default.
• W4385568795 hasAuthorship W4385568795A5054554979 @default.
• W4385568795 hasAuthorship W4385568795A5061261084 @default.
• W4385568795 hasAuthorship W4385568795A5062505370 @default.
• W4385568795 hasAuthorship W4385568795A5067154686 @default.
• W4385568795 hasAuthorship W4385568795A5070656971 @default.
• W4385568795 hasAuthorship W4385568795A5074151633 @default.
• W4385568795 hasAuthorship W4385568795A5079507122 @default.
• W4385568795 hasAuthorship W4385568795A5085714741 @default.
• W4385568795 hasBestOaLocation W43855687951 @default.
• W4385568795 hasConcept C104317684 @default.
• W4385568795 hasConcept C120665830 @default.
• W4385568795 hasConcept C121332964 @default.
• W4385568795 hasConcept C126322002 @default.
• W4385568795 hasConcept C159047783 @default.
• W4385568795 hasConcept C159654299 @default.
• W4385568795 hasConcept C168563851 @default.
• W4385568795 hasConcept C197934379 @default.
• W4385568795 hasConcept C203014093 @default.
• W4385568795 hasConcept C22070199 @default.
• W4385568795 hasConcept C2777704310 @default.
• W4385568795 hasConcept C2780115692 @default.
• W4385568795 hasConcept C2780868878 @default.
• W4385568795 hasConcept C535046627 @default.

• next